AptarGroup, Inc.’s (ATR - Free Report) adjusted earnings per share was 92 cents in fourth-quarter 2020, surpassing the Zacks Consensus Estimate of 90 cents. The bottom line also improved 8% year over year.
On a reported basis, earnings came in at 79 cents per share compared with the year-ago quarter’s 73 cents per share.
Total revenues increased 12% year over year to $749 million during the reported quarter. The top line also beat the Zacks Consensus Estimate of $736 million. Core sales, excluding currency and acquisition effects, increased 5% year over year. Solid underlying demand for medicines drove sale growth in the Pharma segment. Demand for active packaging solutions used with healthcare applications also increased. Further, the company witnessed continued strong demand from personal care and home care markets. This was offset by weakness in beauty markets and lower custom tooling sales.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
AptarGroup, Inc.’s (ATR - Free Report) adjusted earnings per share was 92 cents in fourth-quarter 2020, surpassing the Zacks Consensus Estimate of 90 cents. The bottom line also improved 8% year over year.
On a reported basis, earnings came in at 79 cents per share compared with the year-ago quarter’s 73 cents per share.
Total revenues increased 12% year over year to $749 million during the reported quarter. The top line also beat the Zacks Consensus Estimate of $736 million. Core sales, excluding currency and acquisition effects, increased 5% year over year. Solid underlying demand for medicines drove sale growth in the Pharma segment. Demand for active packaging solutions used with healthcare applications also increased. Further, the company witnessed continued strong demand from personal care and home care markets. This was offset by weakness in beauty markets and lower custom tooling sales.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on AVY - FREE
Get the latest research report on AGCO - FREE
Get the latest research report on ATR - FREE
Get the latest research report on MYE - FREE